PhytoFoundry is building a scalable manufacturing platform for high-value plant bioactives. We develop elite plant cell lines and processes designed to break the cost barrier of plant cell culture.
The demand for plant bioactives is growing, but their supply isn't built to scale. From skincare to medicine, industries depend on molecules that only plants know how to make.
Market size (USD) and CAGR 2025 to 2035, industry estimates.
Farming and extraction struggle to deliver plant molecules reliably. Plant cell culture solves the supply problem, but its economics have kept it confined to a handful of very high-value products.
Slow-growing plants and low bioactive yields. Many valuable molecules sit at trace levels in crops that take months or years to mature.
Weather, harvests and biology create inconsistent supply, with quality that shifts from season to season.
Extraction and purification add cost and complexity, especially where unwanted compounds must be removed.
Paclitaxel, one of the world's most important cancer drugs, has been produced commercially from plant cells grown in bioreactors for decades. The biology works. Season-free, consistent and controlled.
The barrier is cost. Slow growth, low titres and long cycles keep production costs high, so plant cell culture has only paid off where molecules command pharmaceutical prices.
Illustrative: share of each market currently reachable at today's plant cell culture costs.
Making the molecule isn't enough. Making it commercially is.
Source species with the target chemistry
Selected for growth, productivity and stability
Higher yield, shorter cycles, simpler processing
Consistent, traceable, commercially priced
Cell lines chosen for growth, productivity and commercial potential from day one, so scale-up starts from strength.
Higher yield, shorter cycles and simpler downstream processing, designed to run on existing fermentation infrastructure through CDMO partners.
Proprietary datasets and AI-guided optimisation accelerate every programme, so each new cell line is faster and cheaper to develop than the last.
High-value cosmetics provide the route to market. Better cells, simpler processing and larger scale each lower the cost per kilo and open a larger market.
High-value actives where performance and provenance command a premium. Revenue while the platform matures.
Lower cost per kilo from yield gains and larger-scale production unlocks consistent, clean-label actives.
Commodity-scale economics bring plant cell culture into the largest, most price-sensitive markets.
Retinol is a $1.5bn market, but its use comes with recognised limitations. Bakuchiol offers a plant-derived retinol alternative, yet conventional supply depends on slow seed harvests and intensive processing to remove allergens.
PhytoFoundry Bakuchiol is designed to steer cell metabolism towards the target molecule, delivering a cleaner, consistent and locally produced ingredient.
| Conventional Bakuchiol | PhytoFoundry Bakuchiol |
|---|---|
| 6-month raw material cycle | ~2-week production cycle |
| Allergens require intensive processing | Allergen-free target |
| Long-haul supply | Local production |
| Variable supply | Controlled, reliable supply |
We validate the platform with bakuchiol in premium skincare, then apply the same approach to new plant bioactives and larger markets.
PhytoFoundry combines the molecular capability of plant biology with a platform designed for reproducibility and commercial scale.
| Reproducible | Complex plant molecules | Multi-species |
|---|
High-margin B2B ingredient sales to formulators and brands.
Customer-funded development that converts into supply agreements.
Capital-light access to additional markets and geographies.
A platform that gets harder to replicate as it grows, protected by proprietary cell lines, process know-how and data that compounds with every programme.
Deep plant cell culture expertise combined with commercial leadership.
15+ years in plant biotech. Co-founder and production lead at Green Bioactives (2019 to 2025). Inventor on prior-art patents.
6+ years in plant cell culture. Experienced operations and lab manager who led R&D programmes delivering significant yield increases in plant cells.
Business development leader across healthcare, nutraceuticals and manufacturing.
We are raising a £1m pre-seed round to validate our first elite cell line and take it to first commercial supply. Qualified investors can request access to our data room.
Register your interest and we will be in touch within 48 hours.
Access is granted at our discretion to qualified investors. This website does not constitute an offer to invest or a financial promotion. Investments in early-stage companies carry risk.
Thank you. We will review your details and reply to the email provided within 48 hours.